Vertex (Nasdaq: VRTX) to acquire Crinetics (CRNX) in $10B cash deal
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, paying $85.00 per share. The acquisition will add Crinetics' FDA-approved acromegaly drug PALSONIFY and late-stage asset atumelnant to Vertex's portfolio, with potential for over $5 billion in combined annual revenue. The transaction, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to customary conditions.
Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy
Vertex Pharmaceuticals is expanding its rare disease portfolio by acquiring Crinetics Pharmaceuticals for $10 billion. This acquisition adds a fifth business group, endocrine diseases, to Vertex's operations, following the recent US and EU approval of Crinetics' drug Palsonify for acromegaly. The move signals Vertex's strategic growth into new therapeutic areas beyond its established cystic fibrosis franchise.
Vertex spending $10B to buy San Diego biotech in largest-ever acquisition
Vertex Pharmaceuticals is set to acquire San Diego-based Crinetics Pharmaceuticals for $10 billion, marking its largest-ever acquisition. This deal is expected to provide Vertex with near-term revenue opportunities, with the acquired assets projected to generate over $5 billion in combined annual revenue at peak. The acquisition aims to expand Vertex's portfolio and solidify its position in the biotech market.
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex Pharmaceuticals has announced its agreement to acquire Crinetics Pharmaceuticals for $10 billion. This acquisition will expand Vertex's portfolio beyond its primary cystic fibrosis therapies by adding Crinetics' expertise in endocrine disease treatments. Vertex will purchase Crinetics for $85 per share in cash, with the deal valued at $8.8 billion after accounting for acquired net estimated cash.
Vertex Pharma Makes A $10 Billion Deal; Biotech Stock Doubles
Crinetics Pharmaceuticals' stock surged after Vertex Pharmaceuticals announced a $10 billion agreement to acquire the endocrinology-focused biotech company. Crinetics currently markets Palsonify for acromegaly and is developing atumelnant for congenital adrenal hyperplasia, both of which are daily pill treatments. This acquisition aims to integrate Crinetics' pipeline into Vertex Pharma's growing portfolio.
Vertex to buy Crinetics for $10 billion to expand rare-disease business
Vertex Pharmaceuticals announced its intention to acquire Crinetics Pharmaceuticals for approximately $10 billion, aiming to expand its rare-disease portfolio. The acquisition provides Vertex with Palsonify, an FDA-approved drug for acromegaly, and Crinetics' late-stage experimental drug, atumelnant, for congenital adrenal hyperplasia. These drugs are expected to generate over $5 billion in peak annual sales, with the deal projected to close in Q3 2026.
CRTO Stock Clocks Best Day In Nearly 5 Years On 50%+ Premium Buyout Offer From Vista — TTD Edges Higher
Criteo SA (CRTO) shares surged over 21% after reports revealed Vista Equity Partners, in collaboration with Quinti Capital, submitted a takeover bid valuing the company at over 50% premium. While details of the non-public offer remain undisclosed, Criteo's board is expected to review the proposal soon. This news also positively impacted competitor Trade Desk (TTD) and sparked bullish sentiment among retail traders.
Vertex to Buy Crinetics for $10 Billion for Endocrinology Focus
Vertex Pharmaceuticals Inc. has agreed to acquire Crinetics Pharmaceuticals Inc. for $10 billion in an all-cash deal. This acquisition will expand Vertex's focus into endocrinology, specifically targeting treatments for acromegaly and various hormone disorders. The purchase price of $85 per share represents a 102% premium over Crinetics' closing price on the previous Monday.
Stockholders of Two Harbors (NYSE: TWO) approve $12-per-share CrossCountry buyout
Stockholders of Two Harbors Investment Corp. (NYSE: TWO) have approved the planned merger with CrossCountry Mortgage, LLC. Each common share will convert into the right to receive $12.00 in cash plus a pro-rated stub dividend, while preferred shares will be redeemed at $25.00 per share plus accrued dividends. The transaction is expected to close in August 2026, pending remaining regulatory approvals.
Vertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals announced its intent to acquire Crinetics Pharmaceuticals for approximately $10.0 billion cash ($8.8 billion net of estimated cash acquired). This acquisition will add Crinetics' commercialized drug PALSONIFY for acromegaly and the Phase 3 candidate atumelnant for congenital adrenal hyperplasia (CAH), enhancing Vertex's revenue growth and long-term earnings profile. The deal, unanimously approved by both boards, is expected to close in the third quarter of 2026 and could generate over $5 billion in combined annual revenue at peak.
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
Vertex Pharmaceuticals stock has reached a new all-time high, with impressive gains of 17% this year, largely driven by future growth prospects from treatments like Casgevy and Journavx. Despite its growth rate declining lately and its most recent sales up only 8%, the company has several ongoing trials that could unlock more opportunities. However, its current valuation at 31 times trailing earnings and a PEG ratio of 2.0 suggests the stock may be expensive, prompting caution for new investors looking for more reasonably priced growth opportunities.
CRSP - CRISPR Therapeutics AG Options
This article provides detailed financial and stock option data for CRISPR Therapeutics AG (CRSP). It includes key metrics such as market cap, income, sales, EPS, various performance indicators, and insider/institutional ownership percentages, alongside recent trading performance and analyst recommendations.
Vertex Pharmaceuticals (VRTX) Has a Multi-Franchise Cash Engine Bigger Than a Cystic Fibrosis Story
Vertex Pharmaceuticals (VRTX) is transitioning from a company solely defined by its cystic fibrosis (CF) franchise to a multi-franchise cash engine. While CF remains the core profit driver, new products like CASGEVY and JOURNAVX contributed significantly to Q1 2026 growth, demonstrating real diversification. The company's substantial cash reserves of $13.0 billion enable it to fund new launches and pipeline development internally, reinforcing a durable growth strategy beyond its traditional CF reliance.
Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals announced it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for cystic fibrosis patients aged 6 and older with specific CFTR mutations. This LOI follows positive reimbursement recommendations from Canada's Drug Agency and INESSS. The agreement is a significant step towards making ALYFTREK publicly available across Canada, potentially benefiting approximately 3,800 people living with CF.
Vertex Pharmaceuticals (VRTX) Has a Multi-Franchise Cash Engine Bigger Than a Cystic Fibrosis Story
Vertex Pharmaceuticals (VRTX) is transitioning from being solely defined by its cystic fibrosis franchise to a multi-franchise company. While CF still funds the business, newer products like CASGEVY and JOURNAVX now significantly contribute to growth, indicating successful diversification. The company's strong financial position, with $13.0 billion in cash and robust earnings, allows it to fund these new launches and pipeline development internally, changing the investment narrative from a single-engine to a more durable multi-engine business.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350
Cantor Fitzgerald has reiterated a Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a $350 price target, despite expectations of a strong quarterly earnings driven by Repatha and Uplizna performance. The firm noted that Amgen's pipeline lacks significant drivers to extend its recent stock momentum, which has seen shares rise over 10% since June. While InvestingPro analysis suggests Amgen is undervalued with a Fair Value of $394, Cantor Fitzgerald believes a good earnings report alone won't lead to a substantial re-rating given upcoming patent expirations and other pipeline issues.
FDA deepens Vertex's Casgevy label, opening treatment for patients as young as 2
The FDA has expanded the label for Vertex's gene therapy Casgevy, co-developed with CRISPR Therapeutics, to include patients as young as two years old for sickle cell disease and beta thalassemia. This expansion opens treatment to an additional 5,500 children in the U.S., offering earlier intervention to prevent cumulative organ damage. The decision is supported by positive results from ongoing phase 3 trials in pediatric populations.
Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential
Citizens maintained a Market Outperform rating and an $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares, noting the company's stock is currently trading at $60.08, up 6.6% over the past week. The firm believes the expansion of the CASGEVY label to patients aged 2 or older could significantly increase the total addressable market. Citizens also views limited risk from competing therapies like Beam Therapeutics’ risto-cel displacing CASGEVY, highlighting CASGEVY's established integration within transfusion centers.
[EFFECT] Wheeler Real Estate Investment Trust, Inc. SEC Filing
This article reports on an EFFECT SEC filing by Wheeler Real Estate Investment Trust, Inc. (WHLR), with a neutral filing impact and sentiment. The filing, Form S-11, was accepted by the SEC on July 6, 2026. The effectiveness date for the filing was July 2, 2026, at 9:00 A.M.
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next
Vor Biopharma Inc. (VOR) recently saw its stock rise by 27.9% following its inclusion in several Russell indexes. This inclusion enhances the company's visibility and liquidity, but its core investment risks, such as funding the pipeline without further dilution given significant net losses and negative equity, remain unchanged. Future performance heavily depends on clinical progress, regulatory news, and financial updates, with current valuations suggesting potential overvaluation.
Halozyme signs collaboration deal with GSK for oncology targets
Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront payment, potential future milestone payments, and royalties for Halozyme, with the first clinical trial projected for 2026. This collaboration marks Halozyme's first ENHANZE agreement for antibody drug conjugate targets and reflects the company's strong financial momentum and strategic efforts to expand its technology's reach.
ARGX - Argen X SE ADR Options
This article provides a comprehensive overview of Argen X SE ADR (ARGX) stock, including its last closing price, financial performance metrics, and various stock indicators. It details market capitalization, income, sales, P/E ratios, EPS, insider and institutional ownership, profitability, and stock performance over different periods. The data also includes analyst recommendations and target prices.
VRTX - Vertex Pharmaceuticals Inc Options
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its stock performance, market capitalization, income, sales, and various financial ratios. It also highlights institutional and insider ownership, profitability margins, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Is Vertex Pharmaceuticals (VRTX) Undervalued After CASGEVY Won Expanded FDA Approval?
Vertex Pharmaceuticals (VRTX) is under renewed scrutiny following the FDA's expanded approval of CASGEVY for younger children. Despite recent strong share price performance and analysts projecting revenue growth, the company is still considered 3.6% undervalued according to Simply Wall St's narrative, trading at $528.04 against a fair value of $547.72. However, this valuation depends on successful pipeline execution and stable pricing, with potential risks from trial setbacks or tighter reimbursement policies.
Is Vertex Pharmaceuticals (VRTX) Undervalued After CASGEVY Won Expanded FDA Approval?
Vertex Pharmaceuticals (VRTX) is gaining attention after the FDA expanded the use of its gene-editing therapy, CASGEVY, for younger patients with sickle cell disease or beta thalassemia. Despite recent share price gains, Simply Wall St's narrative suggests VRTX is still undervalued, with a fair value estimate of $547.72 against a current trading price of $528.04. The analysis highlights projected revenue and profit margin growth, though it cautions that future success depends on pipeline execution and pricing stability.
Can PTC Therapeutics (PTCT) Be A Bargain On Its Russell Index Additions?
PTC Therapeutics (PTCT) has gained attention due to its inclusion in several Russell indices, influencing fund flows. Despite a strong recent performance and an estimated 58% intrinsic discount, questions remain about whether its current trading price of $83.31 already accounts for future growth, especially concerning its rare disease pipeline. The company is considered 11.3% undervalued by a popular narrative, but its P/S ratio of 8.4x against a fair ratio of 4.8x suggests potential over-optimism.
GRFS - Grifols SA ADR Short Interest
This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability margins, and price performance over different periods. The stock closed at $7.16, showing a slight increase, with a short float of 2.33% and a short interest of 6.01 million shares.
BMRN - Biomarin Pharmaceutical Inc Options
This article provides comprehensive financial data for BioMarin Pharmaceutical Inc. (BMRN), including its last close price, market capitalization, income, sales, and various financial ratios. It also details insider ownership, institutional ownership, profitability margins, and stock performance metrics over different periods.
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
This article reviews the Q1 2026 earnings for AbbVie and other therapeutics companies, highlighting strong performance across the sector. While AbbVie reported increased revenues and an optimistic outlook, Moderna saw the fastest revenue growth, and United Therapeutics had the weakest performance. The article also touches on shifting market narratives from AI to geopolitical risks, emphasizing the importance of fundamental strength in investments.
Vertex (VRTX) Just Won FDA Approval To Treat 5,500 More Young Children
Vertex Pharmaceuticals (VRTX) has received FDA approval for its CASGEVY gene therapy to treat sickle cell disease and transfusion-dependent beta thalassemia in children as young as two years old. This approval expands the eligible pediatric population by approximately 5,500 children in the U.S., marking a significant step in the company's diversification beyond cystic fibrosis treatments. Investors will be watching the adoption rate, reimbursement, and long-term safety data as CASGEVY expands into this younger demographic.
MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales, earnings per share, and stock performance over different periods.
Comparative Analysis of Arcutis and Vertex Biotherapeutics
This article provides a comparative analysis of Arcutis Biotherapeutics and Vertex Pharmaceuticals based on their FY 2025 financial performance, market position, and future outlook. Arcutis showed significant revenue growth but faces stiff competition and patent litigation for its Zoryve product line, while Vertex demonstrated strong profitability and market dominance in rare disease treatments with substantial R&D investments. Analyst ratings suggest a positive outlook for Arcutis stock, despite recent price target downgrades.
GRFS - Grifols SA ADR Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent SEC filing information.
Satellos Bioscience Fast Track Win Fuels DMD Hopes
Satellos Bioscience's SAT-3247, a treatment for Duchenne muscular dystrophy (DMD), has received FDA Fast Track designation, aiming to accelerate its regulatory review. The DMD market is projected for significant growth, reaching US$62.13 billion by 2030, presenting a substantial opportunity for innovative therapies like Satellos's oral small-molecule drug. Several analysts have issued strong buy ratings for Satellos, citing its differentiated approach and upcoming Phase 2 data readouts as key catalysts.
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers
Jay Woods, chief global strategist at Freedom Capital Markets, has recommended investing in the biotech sector, specifically picking Biogen Inc. (BIIB) due to its diversified focus across autoimmune kidney diseases and Alzheimer's, unlike many peers that rely on a single drug. Biogen shares ended Thursday's session 3.04% higher, and the company has several upcoming catalysts, including detailed mid-stage data for its Alzheimer's drug diranersen and a potential FDA decision for a weekly at-home starting dose of LEQEMBI. Despite projecting non-recurring charges in Q2 and Q3 2026, Woods believes the stock's turnaround is truly beginning, with shares still significantly below their 2021 all-time high.
REGN - Regeneron Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Regeneron Pharmaceuticals Inc (REGN), including its latest stock performance, key financial metrics, and company statistics. It covers various aspects like market capitalization, income, sales, dividend information, analyst recommendations, and performance across different timeframes.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. (VRTX) increased by 6.03% to $528.04 on Thursday, marking its second consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index remained largely unchanged, and the Dow Jones Industrial Average saw a rise. The stock's strong performance indicates it outperformed its competitors.
LEGN - Legend Biotech Corp ADR Options
This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The data presented covers market capitalization, earnings per share, sales growth, profitability ratios, and options-related information, offering a comprehensive snapshot for potential investors.
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD
Mirum Pharmaceuticals' stock reached an all-time high of $125.41, bringing its market capitalization to $7.6 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen a 147.06% increase over the last year and strong revenue growth of 50%. Recent developments include pricing $600 million in convertible senior notes, positive analyst coverage with high price targets, and the acquisition of zilurgisertib.
GRFS - Grifols SA ADR Forecast, Target Price
This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and performance over different timeframes. The data suggests a target price of $14.43 against a last close of $7.16, indicating potential upside according to the provided metrics.
H2O America stock hits 52-week high at 61.89 USD
H2O America's stock reached a 52-week high of $61.89, showcasing an 18.17% return over the past year and a 25.33% gain in the last six months, despite being considered overvalued by InvestingPro analysis. The company recently reported Q1 2026 earnings below forecasts and appointed Michael Ambrozewicz as Vice President of Communications.
FDA widens Vertex’s Casgevy use for paediatric patients
The US FDA has expanded the use of Vertex Pharmaceuticals' gene therapy, Casgevy, to include children as young as two years old for treating sickle cell disease and transfusion-dependent beta thalassemia. This marks the first such treatment approved for this paediatric age group, building on its previous approval for patients aged 12 and over. Casgevy, developed with CRISPR Therapeutics, uses CRISPR/Cas9 technology to modify a patient's haematopoietic stem cells, enhancing oxygen delivery and has shown promising results in clinical trials across various age groups.
Vertex Pharmaceuticals stock hits 52-week high at $507.98 By Investing.com
Vertex Pharmaceuticals Inc. (VRTX) stock reached a 52-week high of $507.98, currently trading at $508.96 with a market cap of $127.91 billion, marking a 9.27% increase over the past year. InvestingPro analysis suggests the stock may be overvalued, despite its strong position in the Biotechnology industry and recent FDA approvals for CASGEVY and acceptance of povetacicept for review. Analysts have mixed ratings, with Truist Securities initiating a Buy rating and BMO Capital maintaining a Market Perform.
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
The FDA has approved an expansion for Vertex Pharmaceuticals’ gene therapy Casgevy, allowing its use in children aged 2 years and up with sickle cell disease and transfusion-dependent beta thalassemia. This marks Casgevy as the first genetic medicine for these indications available to young children and was expedited via the Commissioner’s National Priority Voucher program. While initially approved for patients 12 and older, this new approval opens the treatment to approximately 5,500 additional U.S. patients, despite initial slow uptake with the therapy generating $43 million in the first quarter.
Press Release Service: Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals announced that the U.S. FDA has approved the expanded use of CASGEVY for individuals aged 2 years and older with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). This makes CASGEVY the first approved genetic therapy for children as young as two years old with these conditions, significantly expanding eligibility. The approval is expected to provide transformative benefits to a younger patient population, with regulatory reviews for further expansion underway in the Kingdom of Saudi Arabia and the United Kingdom.
Vertex gets paediatric FDA okay for Casgevy gene therapy
Vertex Pharma's gene therapy, Casgevy, has received FDA approval for use in children as young as two with sickle cell disease and beta thalassaemia. This expanded label allows access for an additional 5,500 children in the US, building on its initial approval for patients aged 12 and over. The approval is based on ongoing clinical trials and offers earlier treatment options for life-shortening blood disorders.
Vertex expands CASGEVY to U.S. children as young as 2
Vertex Pharmaceuticals announced that the FDA has approved an expanded use of CASGEVY (exagamglogene autotemcel) for patients aged 2 years and older with severe sickle cell disease or transfusion-dependent beta thalassemia. This expansion makes CASGEVY the first approved genetic therapy for these conditions in children as young as two, increasing the eligible patient population in the U.S. by approximately 5,500 children. The company emphasizes its commitment to transforming the future for these patients and has established a network of authorized treatment centers across the U.S.
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals announced that the U.S. FDA has approved the expanded use of CASGEVY® for patients aged 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia. This marks CASGEVY as the first genetic therapy approved for children as young as 2 for both conditions, potentially benefiting approximately 5,500 more children in the U.S. The company has established a network of authorized treatment centers to provide this one-time genetic therapy.
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two
The U.S. FDA has approved expanded use of Vertex Pharmaceuticals' gene therapy, Casgevy, for children as young as two with inherited blood disorders like sickle cell disease, making it the first such treatment cleared for this age group. Casgevy, a one-time treatment, previously received approval for patients aged 12 and older. The FDA fast-tracked this approval through its new Commissioner's National Priority Voucher program.
Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following the sale, Noci directly holds 58,117 shares of Nuvalent Class A Common Stock.
